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[~Use  of exacerbation score to determine intravenous antibiotic use 
for acute respiratory exacerbations in Cystic Fibrosis 
D. Das, O.L. Bako, S. Javadpour, L.J. Heaf, K.W Southern, D.R Heaf. Respiratory 
Unit, RLCH (Alder Hey) Liverpool, UK 
Acute respiratory exacerbations have a negative impact on lung function and life 
expectancy in CE There is no consensus for the use of IV antibiotics for acute 
exacerbation. A retrospective study of CF patients attending the CF clinic at RLCH 
(Alder Hey) was carried out over a one year period between 2004 and 2005 to 
assess the use of an exacerbation score to determine criteria for using IV antibiotics 
and their efficacy. 10 standard criteria were used to define and calculate an acute 
exacerbation score. 2 patients undergoing evaluation for heart lung transplantation 
were excluded from the study. 
36 patients, median age 12.3 yrs (2.3 16.8 yrs) received 46 courses of IV antibiotics 
for an acute exacerbation. 24(52%) of exacerbations had an exacerbation score of 4 
or more. 13 (28%) had an exacerbation score of 2 or less. Pre and post lung function 
was available on 34 patients. Increased FEV1 > 10% was seen 14/17 (82%) patients 
with an exacerbation score of 4 or more compared to 4/10 (40%) an exacerbation 
score of 2 or less. No difference was seen in weight gain. 
44/46 exacerbations had current sputum or cough swab. 14/46(30%) all strains 
sensitive to all antibiotics used (A), 14/46(30%) all strains sensitive to one 
antibiotic (B), 5/46(11%) one strain or more resistant to all antibiotics (C) and 
13/46(28%) no significant growth (D). Improvement i  FEV1 was independent of
antibiotic sensitivity and FEV1 > 10% was seen in (A) 54%, (B) 84%, (C) 76% 
and (D) 72%. 
Exacerbation score is a useful method of selecting patients who may benefit from 
IV antibiotics. Improvement following IV antibiotics appears to be independent of
antibiotic sensitivity. 
4. Microbiology 
[~]  Routine 3 monthly IV therapy in CF - is it worth it? 
S. Bari, VV2 Shafiq, M.J. Ledson, M.J. Walshaw. Regional adult CF Unit, The 
Cardiothoracic Centre, Liverpool, UK 
Introduction: It is common practice in many paediatric CF units in the UK to 
administer regular outine IV antibiotics in the belief that this maintains the patient's 
pulmonary function. However, such a regime has not been proven in clinical trials, 
and increases the treatment burden and potential side-effects of treatment. We have 
assessed the effect of changing to an "on demand" IV antibiotic service for patients 
transferring to our adult unit from feeder paediatric linics, where "routine" IV 
therapy is widespread. 
Methods: We looked at spirometry (FEV1%predicted) in 18 patients (mean age 
17 years at transition, 8 male) transferring to our adult unit, who had previously 
been receiving routine IV therapy, both in the year prior to transfer and in the first 
and then up to three years later. We also looked at the average number of IV courses 
over the same time period. 
Results: In the year prior to transfer, these patients received an average of 4.1 
IV courses per year (range 3 to 6). There was no difference in the year following 
transfer (mean 3.0 course [0 to 9], P NS), but fewer IVs were given for those who 
had up to 3 year data (mean 2.9 [0 to 7], P 0.015). Also, although there was no 
difference in spirometry in the year following transfer (mean FEV1 67% predicted 
[range 31 to 120] pre transfer versus mean 69% [35 to 110] post transfer; P NS), 
there was a trend to improvement i  the up to 3 year data (mean 75% [37 to 110], 
P 0.06). 
Conclusions: This study has shown that changing the IV antibiotic policy from 
"routine" to "on demand" does not have a negative impact on patients' health in 
those of late teenage years. We believe this improves the quality of care delivered 
to this patient group, by decreasing the treatment burden and reducing the potential 
for side-effects from what can be toxic therapy. 
[• Intrapulmonary concentrations of tobramycin and ceftazidime 
achieved after intravenous administration for the treatment of 
Cystic Fibrosis lung infections 
T.E Moriarty 1, J.C. McElnay 1 , J.S. Elborn 2, M.M. Tunney 1. 1Clinical and 
Practice Research Group, School of Pharmacy, 2Respiratory Medicine Research 
Group, Queen ~' University Belfast, Belfast BT9 7BL, UK 
Treatment ofpulmonary infections in cystic fibrosis (CF) patients routinely involves 
combination antibiotic therapy, the efficacy of which is dependent on the concentra- 
tion of antibiotic(s) at the site of infection rather than in the bloodstream. The aim 
of this study was to determine whether the concentration f antibiotics achieved at 
the site of infection in the lungs were sufficient for inhibition of bacterial growth. 
Sputum samples were collected from 14 CF patients receiving intravenous cef- 
tazidime (3 grams three times daily) and tobramycin (8 mg/kg once daily) com- 
bination therapy. The concentration f both antibiotics in sputum was determined 
by high performance liquid chromatography. Infecting bacteria were also isolated 
and the susceptibility of the isolates to ceftazidime and tobramycin determined by 
measurement of the minimum inhibitory concentration (MIC). 
The mean pre-dose sputum tobramycin and ceftazidime concentrations were 0.9 
and 3.5 gg/ml, respectively. The mean peak sputum tobramycin and ceftazidime 
concentrations were 3.8 and 11.8 gg/ml, respectively. The MIC of ceftazidime was 
exceeded in 16% of samples. The MIC of tobramycin was not exceeded in any 
samples. 
This study has shown that intravenous administration f tobramycin or ceftazidime 
at the recommended doses for the treatment of CF lung infection does not achieve 
adequate sputum concentrations of either antibiotic. 
Recording of antibiotic allergies and intolerances for patients with 
Cystic Fibrosis 
I. Temple, R. Gore, M.E. Dodd, A.K. Webb, A.M. Jones. Manchester Adult Cystic 
Fibrosis' Centre, UK 
Introduction: Our cystic fibrosis (CF) centre's protocol is that patient allergies 
should be recorded on the spine of the casenotes (SC), the patient's drug information 
card (DI) and, during inpatient admissions, the drug kardex (DK). Accurate 
recording of allergies is important to prevent exposure of sensitised individuals 
to antibiotics to which they are known to be allergic. It is also important that 
antibiotic options are not unnecessarily limited, as there are only a small number 
of antibiotics available against the typical CF pathogens, and there is an increasing 
prevalence of multiresistance among CF pathogens. 
Method: We audited casenotes for documentation f allergies and intolerances at 
all 3 recommended sites for recording. We audited all available casenotes present 
in the centre's administration ffice in a one-sweep a-z method but did not search 
for absent files. 
Results: 226 casenotes were audited of a CF centre population of 262 patients. 
86 (38%) patients were documented asallergic to at least 1 antibiotic. 99 (43.8%) 
patients were documents as intolerant of at least 1 × antibiotic. 118 (52%) patients 
were unable to receive at least 1 antibiotic either due to an intolerance or an 
allergy. Allergies were recorded in the DI in 85%, DK in 71% and SC in 35%, and 
intolerances in the DI in 96%, DK in 96% and SC in 21%. The type of allergy was 
not recorded in 56% of cases. 
Conclusions: Patients with CF have a high prevalence of antibiotic allergies and 
intolerances. Our current recording of antibiotic allergy/intolerances needs to be 
improved. We propose to streamline our recording of antibiotics into a specific 
chart. 
